Assessment of Quantitative Magnetic Resonance Imaging Background Parenchymal Enhancement Parameters to Improve Determination of Individual Breast Cancer Risk.
Journal
Journal of computer assisted tomography
ISSN: 1532-3145
Titre abrégé: J Comput Assist Tomogr
Pays: United States
ID NLM: 7703942
Informations de publication
Date de publication:
Historique:
pubmed:
28
7
2018
medline:
19
1
2019
entrez:
28
7
2018
Statut:
ppublish
Résumé
The aims of this study were to identify optimal quantitative breast magnetic resonance imaging background parenchymal enhancement (BPE) parameters associated with breast cancer risk and compare performance to qualitative assessments. Using a matched case-control cohort of 46 high-risk women who underwent screening magnetic resonance imaging (23 who developed breast cancer matched to 23 who did not), fibroglandular tissue area, BPE area, and intensity metrics (mean, SD, quartiles, skewness, and kurtosis) were quantitatively measured at varying enhancement thresholds. Optimal thresholds for discriminating between cancer and control cohorts were identified for each metric and performance summarized using area under the receiver operating characteristic curve. Women who developed breast cancer exhibited greater BPE area (adjusted P = 0.004) and higher intensity statistics (adjusted P < 0.004, except skewness and kurtosis with P > 0.99) than did control subjects, with areas under the receiver operating characteristic curve ranging from 0.75 to 0.78 at optimized thresholds. Elevated quantitative BPE parameters, related to both area and intensity of enhancement, are associated with breast cancer development.
Identifiants
pubmed: 30052617
doi: 10.1097/RCT.0000000000000774
pmc: PMC6331225
mid: NIHMS970992
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-92Subventions
Organisme : NCI NIH HHS
ID : R01 CA203883
Pays : United States
Références
J Clin Epidemiol. 2001 Aug;54(8):774-81
pubmed: 11470385
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69
pubmed: 16775176
CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89
pubmed: 17392385
J Clin Oncol. 2009 Dec 20;27(36):6124-8
pubmed: 19884532
Am J Hum Genet. 1991 Feb;48(2):232-42
pubmed: 1990835
Ann Intern Med. 2009 Nov 17;151(10):727-37, W237-42
pubmed: 19920273
J Clin Oncol. 2010 Aug 10;28(23):3779-83
pubmed: 20625126
Radiology. 2011 Jul;260(1):50-60
pubmed: 21493794
Radiology. 2011 Sep;260(3):658-63
pubmed: 21712474
Breast Cancer Res. 2011;13(6):223
pubmed: 22114898
J Clin Oncol. 2014 Jul 20;32(21):2224-30
pubmed: 24934793
AJR Am J Roentgenol. 2014 Jul;203(1):209-15
pubmed: 24951217
AJR Am J Roentgenol. 2015 May;204(5):1120-4
pubmed: 25905951
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
pubmed: 2593165
Radiology. 2015 Aug;276(2):371-80
pubmed: 25965809
Br J Radiol. 2015;88(1056):20150417
pubmed: 26462852
Magn Reson Imaging. 2016 Feb;34(2):173-6
pubmed: 26597834
Ann Intern Med. 2016 Feb 16;164(4):236-43
pubmed: 26756332
Curr Probl Diagn Radiol. 2016 Sep-Oct;45(5):297-303
pubmed: 27039221
J Comput Assist Tomogr. 2016 May-Jun;40(3):428-35
pubmed: 27192501
PLoS One. 2016 Jul 05;11(7):e0158573
pubmed: 27379395
Sci Rep. 2017 May 18;7(1):2115
pubmed: 28522877
J Magn Reson Imaging. 2018 Jun;47(6):1685-1691
pubmed: 29140576
Natl Cancer Inst Monogr. 1985 May;67:65-74
pubmed: 4047153
Am J Roentgenol Radium Ther Nucl Med. 1973 Mar;117(3):686-9
pubmed: 4693025